|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Research
and Development
During the year ended 31 December 2008, our expenditures on
R&D amounted to $334.4 million, compared to
$271.7 million for the year ended 31 December 2007.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. (p) Research
and development
R&D costs are expensed as incurred. Acquired in-process
research and development is expensed as incurred. Costs to
acquire intellectual property, product rights and other similar
intangible assets are capitalized and amortized on a
straight-line basis over the estimated useful life of the asset.
The method of amortization chosen best reflects the manner in
which individual intangible assets are consumed.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Research
and Development
During the year ended 31 December 2007, our expenditures on
R&D amounted to $271.7 million, compared to
$226.2 million for the year ended 31 December 2006.
This excerpt taken from the ELN 20-F filed Feb 28, 2008. (o) Research
and development
R&D costs are expensed as incurred. Acquired in-process
research and development is expensed as incurred. Costs to
acquire intellectual property, product rights and other similar
intangible assets are capitalized and amortized on a
straight-line basis over the estimated useful life of the asset.
The method of amortization chosen best reflects the manner in
which individual intangible assets are consumed.
This excerpt taken from the ELN 6-K filed Mar 30, 2007. Research
and Development
During the year ended 31 December 2006, our expenditures on
R&D amounted to $224.6 million, compared to
$249.1 million for the year ended 31 December 2005.
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Research and Development
During the year ended 31 December 2005, our expenditures on
research and development amounted to $249.1 million
compared to $262.6 million for the year ended
31 December 2004.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. (o) Research
and development
R&D costs are expensed as incurred. Acquired in process
research and development arising on business combinations is
expensed on acquisition. Costs to acquire intellectual property,
product rights and other similar intangible assets are
capitalized and amortized on a straight-line basis over the
estimated useful life of the asset. The method of amortization
chosen best reflects the manner in which individual intangible
assets are consumed.
This excerpt taken from the ELN 6-K filed Oct 27, 2005. Research & Development
Tysabri (Natalizumab)
The comprehensive Tysabri safety evaluation for multiple sclerosis (MS), Crohn’s Disease (CD) and rheumatoid arthritis has been completed and the findings resulted in no new confirmed cases of progressive multifocal leukoencephalopathy (PML). The companies have previously reported three confirmed cases of PML, two of which were fatal. On September 26, 2005, Elan and Biogen Idec announced the submission of a supplemental Biologics License Application (sBLA) for Tysabri to the U.S. Food and Drug Administration (FDA) for the treatment of MS. The companies have requested Priority Review designation from the FDA. The sBLA includes final two-year data from the Phase III AFFIRM monotherapy trial and SENTINEL add-on trial with AVONEX® (Interferon beta-1a) in MS, the integrated safety assessment of patients treated with TYSABRI in clinical trials, a revised label and a risk management plan. The companies have also submitted a similar data package to the European Medicines Agency. The process to restart clinical trials in MS is ongoing.
This excerpt taken from the ELN 6-K filed Apr 11, 2005. (C) Research and Development Exceptional R&D expenses were $23.8 million. These mainly relate to product impairments of $7.1 million, severance/relocation costs of $8.2 million and similar costs arising from our restructuring as a part of the recovery plan. | EXCERPTS ON THIS PAGE:
|
| |||||||
